Option chain shows key data for Innate Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Innate Pharma.

Innate Pharma (NASDAQ:IPHA) Stock, Option Chain

Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

The Boeing Company (BA)

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CLEU

IPHA

KARO

NRIX

Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday

Biotech

Penny Stocks

Health Care

Movers

General

The FDA has placed a clinical hold on Innate Pharma SA&#39;s (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL). 

Regulatory Hurdle For Innate Pharma&#39;s Blood Cancer Studies

Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis

Small Cap

EWTX

PRVB

SGEN

TBPH

TLSA

Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the clinical stage.

Innate Pharma S.A. - American Depositary Shares

Innate Pharma SA

WIIM

BRZE

Braze shares are trading higher following a report suggesting the company could be a target for an acquisition.

RBC Capital analyst Andrew Wong maintains Cameco (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CCO#TSX">CCO</a>) with a Outperform and raises the price target from C$75 to C$90.

Price Target

Analyst Ratings

TSX:CCO

RBC Capital Maintains Outperform on Cameco, Raises Price Target to C$90

Geopolitical tensions between Russia and Ukraine are once again roiling global energy markets, with rising prices raising concerns over the potential economic impact <a href="https://www.benzinga.com/topic/inflation">on U.S. consumer bills.</a> 
On Thursday, Russia launched an intercontinental ballistic missile (ICBM) from the Astrakhan region during an overnight strike on Dnipro, Ukraine, Reuters reported, citing the Ukrainian air force. 
As reported by Reuters, security experts said this marks the first use of an ICBM in a military conflict. The missiles are designed for nuclear warhead delivery. There is no indication the missile was nuclear-armed, Reuters said. 
Western officials disagree with Ukraine&#8217;s assessment, The New York Times <a href="https://www.nytimes.com/2024/11/21/world/europe/russia-ballistic-missile-ukraine-war.html">said in a report</a>, and say the missile was likely of intermediate range. The Times said the officials spoke anonymously in order to discuss a private Western intelligence assessment. 
The Ukrainian air force said the missile was fired from over 435 miles away, targeting the central-eastern city of Dnipro. 
While the attack caused injuries to two people, the extent of the damage remains unclear. Ukrainian president Volodymyr Zelenskyy condemned the move, commenting on X: &#8220;Our insane neighbour has once again revealed its true nature.&#8221;
The move adds to escalating tensions, coming on the heels of Ukraine firing two Western-made missiles at Russia on Tuesday and Wednesday, after receiving approval from the White House <a href="https://www.benzinga.com/news/global/24/11/42064198/putin-revises-nuclear-doctrine-for-broader-strikes-after-us-backed-ukrainian-attack-markets-drop-bonds-gain">to target Russian territory.</a>
<h3 class="wp-block-heading">US Natural Gas Prices Spike, Eye Best Monthly Performance Since July 2022</h3>
In the wake of these heightened external geopolitical risks, U.S. natural gas prices surged. 
Futures tied to the Henry Hub benchmark – as tracked by the United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) – jumped more than 6% on Thursday, reaching $3.40 per million British thermal units — the highest level since early November 2023.
The commodity is now up 50% for November, positioning itself for its strongest monthly rally since July 2022.
Natural gas demand in the U.S. has been driven by plummeting temperatures, intensifying the need for heating. 
The National Oceanic and Atmospheric Administration warned on Thursday of the season&#8217;s first significant snowfall in the central and northern Appalachians, with heavy accumulation expected through Friday.
&#8220;Higher elevations will have the best chance of significant accumulations, however even the lower elevations of central and northern Pennsylvania and south central New York will likely see some accumulation of snow,&#8221; the NOAA wrote in a post on X.
The U.S. Energy Information Administration is set to release weekly natural gas inventory change later Thursday.
Europe's natural gas market is grappling with fresh supply concerns as winter approaches after Austria&#8217;s OMV Group disclosed over the weekend that it will no longer receive volumes from its long-term contract with Russia's Gazprom.
<h3 class="wp-block-heading">WTI Oil Prices Climb, Gold Eyes 4th Straight Positive Day</h3>
The ripple effects of escalating geopolitical tensions also extended to crude oil markets. 
West Texas Intermediate crude futures, tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), climbed 2.2% on Thursday morning, trading at $70 per barrel — the highest level since Nov. 11.
Gold continued to attract demand for safe-haven assets, with the precious metal rising 0.6% to $2,665 per ounce, eyeing the fourth straight session of gains. 
Bitcoin rose 3%, hitting a new peak of $98,367.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42097545/feds-bowman-warns-on-inflation-risks-signals-neutral-rate-may-be-closer">Fed&#8217;s Bowman Warns On Inflation, Says Neutral Interest Rates May Be Closer &#8216;Than We Currently Think&#8217;</a></li>
</ul>

Specialty ETFs

Commodities

Global

Economics

ETFs

$BTC

Natural Gas Prices Spike To Over 1-Year Highs, Oil Surges To $70 As Ukraine Says Intercontinental Ballistic Missile Fired By Russia

Janney Montgomery Scott analyst Robert Farnam downgrades Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) from Buy to Neutral and announces $176 price target.

Downgrades

Janney Montgomery Scott Downgrades Hanover Insurance Gr to Neutral, Announces $176 Price Target

RBC Capital analyst Irene Nattel reiterates Metro (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MRU#TSX">MRU</a>) with a Sector Perform and maintains C$90 price target.

Reiteration

TSX:MRU

RBC Capital Reiterates Sector Perform on Metro, Maintains C$90 Price Target

SRAD

Sportradar shares are trading higher after the company announced a multiyear agreement with MLB to provide sports performance analysis of prospects using its Synergy Coaching and Scouting solution.

Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) disclosed a contract from renewable energy company, RWE AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RWEOY#OTC">RWEOY</a>), to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42105671/rwe-to-harness-ai-driven-weather-modelling-with-hpe-private-cloud-ai" rel="noreferrer noopener">enhance weather data analysis</a>.
RWE has adopted HPE Private Cloud AI, part of the NVIDIA AI Computing by HPE portfolio, to streamline weather model data processing and enhance information retrieval with retrieval-augmented generation (RAG).
The on-premise solution allows RWE&#8217;s researchers to rapidly deploy private cloud AI infrastructure within policy frameworks, enabling quicker experimentation and scaling of AI projects across various domains and regions.
HPE Private Cloud AI, co-developed with NVIDIA and delivered via the HPE GreenLake cloud, offers RWE a streamlined platform for infrastructure management, process automation, and workload orchestration, including sustainability metrics.
This allows RWE&#8217;s research team to focus on model development, accelerating time-to-market and providing a competitive edge in the renewable energy sector.
Fidelma Russo, EVP &amp; GM, Hybrid Cloud &amp; CTO at HPE, said, &#8220;The ability to fine tune and inference AI-driven weather models will be a key enabler to unlock higher efficiencies for RWE&#8217;s renewable energy portfolio and will give them a significant competitive advantage in the market.&#8221;
&#8220;HPE Private Cloud AI is a unique turnkey solution that enables RWE&#8217;s researchers to reach the market quicker and handle massive datasets.&#8221;
Yesterday, Deloitte expanded its collaboration with HPE to implement the newly launched HPE Private Cloud AI with NVIDIA, enhancing its AI capabilities and accelerating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42085548/deloitte-and-hewlett-packard-enterprise-collaborate-to-deliver-private-cloud-ai-capabilities" rel="noreferrer noopener">deployment of Generative AI solutions</a>.
Investors can gain exposure to the stock via&nbsp;First Trust S&amp;P 500 Diversified Dividend Aristocrats ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNGZ#NASDAQ">KNGZ</a>) and Roundhill Generative AI &amp; Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHAT#NYSE">CHAT</a>).
Price Action: HPE shares are up 0.99% at $21.39 premarket at the last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42105704" target="_blank" rel="noreferrer noopener">SpaceX CEO Elon Musk Reveals Technical Glitch That Led Company To Drop Key Objective Of Starship&#8217;s 6th Test Flight</a></li>
</ul>

Equities

Large Cap

Contracts

CHAT

KNGZ

Rwe Ag Ord Bearer Dm5 American Depository Receipt

RWEOY

HPE Powers RWE's Renewable Energy with AI Weather Modeling

RBC Capital analyst Andrew Wong maintains NexGen Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NXE#TSX">NXE</a>) with a Outperform and raises the price target from C$10 to C$15.

TSX:NXE

RBC Capital Maintains Outperform on NexGen Energy, Raises Price Target to C$15

ROAD

Construction Partners shares are trading higher after the company raised its FY25 revenue guidance.

Addentax Group Corp. ("Addentax" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>), an integrated service provider focusing on garment manufacturing, logistics services, property management, and subleasing, has announced the signing of a Memorandum of Understanding (MOU) for nationwide strategic cooperation with Shenzhen Yingbin Brand Development Co., Ltd. ("Yingbin Brand"), a prominent brand management company headquartered in Guangdong.

ATXG

Addentax Group Corp. Announces Signing Of MOU For Strategic Cooperation With Shenzhen Yingbin Brand Development Co., Ltd., Offering A Wide Range Of Services In Brand Supply Chain Management, Product Supply Chain Solutions, And Marketing Supply Chain Strategies

Maximus shares are trading lower after the company on Wednesday reported worse-than-expected Q4 adjusted EPS results.

iQIYI shares are trading lower despite a Q3 earnings beat.

RBC Capital analyst Pammi Bir maintains Riocan REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/REI#TSX">REI</a>) with a Outperform and raises the price target from C$21 to C$22.

TSX:REI

TSX:REI/UN

RBC Capital Maintains Outperform on Riocan REIT, Raises Price Target to C$22

On Wednesday, Pyxis Oncology, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42099028/pyxis-oncology-announces-favorable-preliminary-pyx-201-clinical-phase-1-part-1-data" rel="noreferrer noopener">multiple solid tumors</a>.
Among evaluable Head and Neck Squamous Cell Carcinoma (HNSCC) patients treated at an identified dose range of PYX-201 from 3.6 – 5.4 mg/kg (n=6), a confirmed 50% objective response rate (ORR) was observed, including one confirmed complete response (CR) and two confirmed partial responses (PR).
The company additionally announced a Clinical Trial Collaboration Agreement with Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) for a Pyxis Oncology-sponsored study of PYX-201 in combination with Merck&#8217;s Keytruda (pembrolizumab) in patients with 1L and 2L HNSCC, HR+/HER2- breast cancer, and triple-negative breast cancer (TNBC) and sarcoma.
<ul>
<li>PYX-201 and Keytruda combination dose escalation and expansion study in 1L and 2L HNSCC with preliminary clinical data readout expected in the second half of 2025.</li>
<li>PYX-201 monotherapy study in 2L and 3L HNSCC patients who are platinum and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the second half of 2025.</li>
<li>PYX-201 monotherapy study in 2L and 3L HNSCC patients who are EGFR and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the first half of 2026.</li>
</ul>
Exploratory PYX-201 Phase 1 monotherapy expansion cohorts are planned for ovarian cancer, NSCLC, HR+/HER2 breast cancer, TNBC, and sarcoma. Preliminary clinical data are expected in the second half of 2025.
<ul>
<li>The company also expects to initiate the PYX-201 and Keytruda combination study in HR+/HER2 breast cancer, TNBC, and sarcoma, with preliminary clinical data expected in the second half of 2025 and the first half of 2026.</li>
<li>Preclinical studies of PYX-201 combined with other agents in ovarian cancer and NSCLC will commence in 2025, followed by clinical studies with preliminary clinical data expected in 2026.</li>
</ul>
PYX-201 demonstrated favorable preliminary tolerability profile data with low incidence of dose discontinuation, interruptions, or delays due to treatment-related adverse events.
William Blair analysts note that PYX-201 shows limited effectiveness outside of head-and-neck cancer, with only 8.7% of patients (2 out of 23) responding to tolerable doses of 3.6 mg/kg, 4.4 mg/kg, and 5.4 mg/kg.
&#8220;At this point, we are unsure whether the three unconfirmed responses could ultimately be confirmed,&#8221; the analysts writes.
The analysts has reduced the probability of success for PYX-201 to 10% from 35%. The updated fair value stands at $250 million or roughly $4.25 per share, comprising $1.77 per share from PYX-201 and $2.48 per share of cash.
With no major stock-moving events expected until the second half of 2025, the analysts estimate the stock will trade around $2.80 per share soon. William Blair says it includes $1.77 per share for PYX-201 and $1.07 for remaining cash by late 2025.
William Blair downgrades <a target="_blank" href="https://www.benzinga.com/quote/PYXS/analyst-ratings" rel="noreferrer noopener">Pyxis to Market Perform</a>, saying, &#8220;Since we view the head-and-neck cancer results as difficult to differentiate, coupled with modest activity in other solid tumor histologies.&#8221;
Price Action: PYXS stock is down 42.15% to $2.21 during premarket trading on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42098028/qualcomms-shift-from-handsets-to-ai-and-automotive-wins-analysts-confidence" target="_blank" rel="noreferrer noopener">Qualcomm&#8217;s Shift From Handsets To AI And Automotive Wins Analysts&#8217; Confidence</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

PYXS

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

SWVL

Swvl Signs Three-Year Contract With G4S In Saudi Arabia To Provide SaaS-Based Mobility Solutions, Enhancing Fleet Efficiency Across Riyadh, Jeddah, And Dammam With Over 14,000 Monthly Trips; Financial Terms Not Disclosed

NVDA

NVIDIA shares are trading higher following the company's Q3 earnings report.

Compass Point analyst Floris Van Dijkum upgrades Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) from Neutral to Buy and maintains the price target from $17 to $17.

Upgrades

Compass Point Upgrades Pebblebrook Hotel to Buy, Maintains Price Target to $17

RBC Capital analyst Pammi Bir maintains SmartCentres REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SRU#TSX">SRU</a>) with a Outperform and raises the price target from C$27 to C$28.

TSX:SRU

TSX:SRU/UN

RBC Capital Maintains Outperform on SmartCentres REIT, Raises Price Target to C$28

As of Nov. 21, 2024, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Natural Gas Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>)</h3>
<ul>
<li>On Nov. 14, Natural Gas Services posted better-than-expected quarterly earnings. &#8220;We delivered another quarter of significant top and bottom-line growth, as well as a material increase in net cash provided by operating activities, as we further grow and optimize our business,&#8221; said Justin Jacobs, Chief Executive Officer. &#8220;Compression demand, particularly in the Permian Basin, remains robust. We continue to capitalize on our favorable industry position, innovative compression units, and strong customer relationships to increase investments in our large horsepower fleet as we look to drive growth in rental fleet horsepower, rental revenue, and cash flow.&#8221; The company's stock gained around 32% over the past month and has a <a href="https://www.benzinga.com/quote/NGS">52-week high of $26.00</a>.</li>
<li>RSI Value: 81.77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>NGS Price Action: Shares of Natural Gas Services closed at $25.91 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Range Resources Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>)</h3>
<ul>
<li>On Oct. 22, the company posted better-than-expected quarterly earnings. Dennis Degner, the Company&#8217;s CEO, commented, &#8220;This month marks the 20th anniversary of Range drilling the first commercial Marcellus shale well. The Marcellus and Utica now produce nearly one-third of U.S. natural gas, and the U.S. has become the leading global supplier of safe, clean, affordable natural gas. We are tremendously proud of the role Range has played in this hugely impactful achievement and we are even more excited about what the future holds as global energy demand increases, improving the quality of life for billions of people living in energy poverty.&#8221; The company's stock gained around 17% over the past month and has a <a href="https://www.benzinga.com/quote/RRC">52-week high</a> of $39.33.</li>
<li>RSI Value: 76.05</li>
<li>RRC Price Action: Shares of Range Resources closed at $35.16 on Wednesday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42094434/top-3-consumer-stocks-that-are-ticking-portfolio-bombs">Top 3 Consumer Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Short Ideas

Top 2 Energy Stocks You May Want To Dump This Month

<ul>
<li>MSTR</li>
<li>NVDA</li>
<li>$BTC</li>
<li>CORN</li>
<li>MARA</li>
<li>COIN</li>
<li>SNOW</li>
<li>TSLA</li>
<li>AI</li>
<li>GLD</li>
</ul>
data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

COIN

CORN

MARA

MSTR

SNOW

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 21, 2024 (Via Swaggy Stocks)

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Innate Pharma (IPHA – Research Report) on September 13 and set a price target of $5.00....

Innate Pharma (IPHA) Receives a Buy from Evercore ISI

Innate gets FDA clearance for Phase 1 study for IPH4502 ADC candidate

In a report released on September 26, Justine Telliez from Kepler Capital maintained a Hold rating on Innate Pharma SA (IPHYF – Research Report), w...

Kepler Capital  Reaffirms Their Hold Rating on Innate Pharma SA (IPHYF)

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Innate Pharma (IPHA – Research Report) on October 4. The company's shares close...

Leerink Partners Reaffirms Their Buy Rating on Innate Pharma (IPHA)

Innate Pharma appoints Jonathan Dickinson as new CEO and Chairman of executive board

Innate Pharma (IPHA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth...

Innate Pharma's IPH4502: Promising Anti-Tumor Activity and Broad Application Prospects Justify Buy Rating

Innate Pharma S.A. 2024 Q3 - Results - Earnings Call Presentation

Innate Pharma reports 9M results

Innate Pharma S.A. (IPHA) Q3 2024 Earnings Call Transcript

Innate Pharma (IPHA) announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, Innate's proprieta...

Innate Pharma publishes IPH6501 data in Science Immunology

IPHYF

Press Releases

Innate Pharma Reports First Half 2024 Business Update and Financial Results

Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors

Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024

Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

Comments

Innate Pharma

Innate Pharma (IPHA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga